Company Insights - UBS has a positive outlook on uniQure (QURE.US) and PTC Therapeutics (PTCT.US), giving both companies a buy rating based on optimistic feedback from a neurologist regarding their treatments for Huntington's disease (HD) [1] - The neurologist treats approximately 100 HD patients, with 85% showing symptoms, and believes that if AMT-130 is available soon, about 25% of patients would be prescribed this gene therapy, while 40% would be suitable for PTC-518 [1][2] - The report highlights the importance of upcoming data updates from PTC in Q2 and uniQure in Q3, which are expected to demonstrate sustained efficacy [2] Industry Opportunities and Challenges - The Huntington's disease field presents significant opportunities for both PTC and uniQure due to high patient awareness and strong treatment willingness [2] - There remains a substantial unmet medical need in the HD treatment landscape, with disease-modifying therapies offering important opportunities, although the data released on May 5 is still early and complex [2] - Regulatory developments for uniQure later this quarter are seen as key catalysts that could enhance investor confidence, while the long-term follow-up data from uniQure has shown some supportive evidence despite historical challenges in HD research [2]

uniQure (QURE) closed the last trading session at $12.81, gaining 32.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $33.50 indicates a 161.5% upside potential.The average comprises 10 short-term price targets ranging from a low of $20 to a high of $70, with a standard deviation of $15.33. While the lowest estimate indicates an increase of 56.1% from the current price level, the ...

uniQure (QURE) Q1 2025 Earnings Call May 09, 2025 08:30 AM ET Company Participants Chiara Russo - Senior Director - IRMatt Kapusta - CEOWalid Abi-Saab - Chief Medical Officer & Member of Management BoardChristian Klemt - CFODebjit Chattopadhyay - Senior Managing DirectorPaul Matteis - Managing Director, Head of Therapeutics ResearchPatrick Trucchio - Managing DirectorJenny Gonzalez-Armenta - Equity Research AssociateUy Ear - Vice PresidentSuzanne van Voorthuizen - Head of Life Sciences Equity Research Confe ...

uniQure (QURE) Q1 2025 Earnings Call May 09, 2025 08:30 AM ET Speaker0 Good day and thank you for standing by. Welcome to the UniCure First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you'll need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To answer your question, press ...

UniQure (QURE) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to loss of $1.36 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 23.36%. A quarter ago, it was expected that this human gene therapy company would post a loss of $0.44 per share when it actually produced a loss of $1.50, delivering a surprise of -240.91%.Over the last four quarters, the company ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-36294 uniQure N.V. (Exact name of Registrant as specified in its charter) The Netherlands (Sta ...

Exhibit 99.1 uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress ~ AMT-130 granted Breakthrough Therapy designation by FDA~ ~ Initial safety data from third cohort of Phase I/II study show AMT-130 continues to be generally well-tolerated, with no treatment-related serious adverse events ~ ~ Held Type B FDA meetings in the first and second quarters of 2025 to advance BLA preparations for AMT- 130; regulatory update expected in the second quarter of 2025 ~ ~ AMT-26 ...

~ AMT-130 granted Breakthrough Therapy designation by FDA ~ ~ Initial safety data from third cohort of Phase I/II study show AMT-130 continues to be generally well-tolerated, with no treatment-related serious adverse events ~ ~ Held Type B FDA meetings in the first and second quarters of 2025 to advance BLA preparations for AMT-130; regulatory update expected in the second quarter of 2025 ~ ~ AMT-260 clinical data from first patient to be presented at Epilepsy Therapies & Diagnostics Development Symposium o ...

Both my spouse and I have a DPhil from Oxford University. Mine is in Cell Physiology and his is in Bio-organic Chemistry. Growing wealth sustainably is our goal. Investing in R&D biotech is our focus. My articles and comments are not financial advice, as I am not a financial adviser. I wrote SA articles for readers who find reading & considering SA articles helpful to their own research. All the best in seeking & finding alpha through biotech investing!Analyst’s Disclosure: I/we have a beneficial long posit ...

~ uniQure to host inaugural earnings call on Friday, May 9, 2025 at 8:30 a.m. ET ~LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 05, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report first quarter 2025 financial results before market open on Friday, May 9, 2025. Management will then host a conference call at 8:30 a.m. ET. As the Company advances its pipeline and AMT-130 toward a BLA ...